Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial

Trifunctional Bispecific Antibodies Induce Tumor-Specific T Cells and Elicit a Vaccination Effect

(2012) Nina Eissler et al.   CANCER RESEARCH

Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model

(2012) Peter Ruf et al.   Journal of Translational Medicine

Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity

(2011) Juergen Hess et al.   Future Oncology

Bispecific Antibodies for Cancer Immunotherapy

(2010) Dafne Müller et al.   BIODRUGS

Bispecific antibodies for cancer therapy

(2010) Patrick Chames et al.   mAbs

Relapse after allogeneic stem cell transplantation

(2010) A John Barrett et al.   Expert Review of Hematology

The allogeneic graft-versus-cancer effect

(2009) Olle Ringdén et al.   BRITISH JOURNAL OF HAEMATOLOGY

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

(2008) I. F. Khouri et al.   BLOOD

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion

(2008) R Buhmann et al.   BONE MARROW TRANSPLANTATION

Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody

(2008) Shoshana Morecki et al.   EXPERIMENTAL HEMATOLOGY

Ertumaxomab: a trifunctional antibody for breast cancer treatment

(2008) Philipp Kiewe et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti‐CD20 × anti‐CD3), mediates efficient killing of B‐cell lymphoma cells even with very low CD20 expression levels

(2008) Michael Stanglmaier et al.   INTERNATIONAL JOURNAL OF CANCER